Genotoxicity testing of biotechnology-derived products: Report of a GUM task force

Mutation Research - Reviews in Mutation Research

Volumn 436, Issue 2, 1999, Pages 137-156

  Gocke, Elmar ^a   Albertini, Silvio ^a   Brendler Schwaab, Susanne ^b   Müller, Lutz ^c   Suter, Willi ^d   Würgler, Friedrich E ^e  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b BAYER AG   (Germany)

^c Fed Inst Drugs and Med Devices   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e ETH ZURICH   (Switzerland)

Author keywords

Biotechnology products; Compilation of industry studies; Genotoxicity; Relevance; Review of literature

Indexed keywords

BIOLOGICAL PRODUCT; MUTAGENIC AGENT; RECOMBINANT PROTEIN;

ANIMAL; BIOTECHNOLOGY; DECISION TREE; DRUG CONTAMINATION; EUROPE; HUMAN; MUTAGEN TESTING; QUESTIONNAIRE; REVIEW; STANDARD;

ANIMALS; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; DECISION TREES; DRUG CONTAMINATION; EUROPE; HUMANS; MUTAGENICITY TESTS; MUTAGENS; QUESTIONNAIRES; RECOMBINANT PROTEINS;

EID: 0033093819     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00002-2     Document Type: Article

References (50)

1. J.H. Levy, The human inflammatory response, J. Cardiovasc. Pharmacol. 27 (1996) S31-S37.
2. J.R. Lazutka, Genetic toxicity of cytokines, Mutat. Res. 361 (1996) 95-105.
3. S.M. Morris, A. Aidoo, O.E. Domon, L.J. McGarrity, R.L. Kodell, H.M. Schol, W.O. Hinson, J.L. Pipkin, D.A. Casciano, Effect of interleukin-2 on cell proliferation, sisterchromatid exchange induction, and nuclear stress protein phosphorylation in PHA-stimulated Fischer 344 rat spleen lymphocytes: modulation by 2-mercaptoethanol, Environ. Mol. Mutagen. 15 (1990) 10-18.
4. F. Hild, M. Freund, C. Fonatsch, Chromosomal aberrations during Interferon therapy for chronic myelogenous leukaemia, New Engl. J. Med. 325 (1991) 132.
5. B.B. Aggarwal, P.K. Gadhia, V.L. Hopwood, B.J. Dave, S. Risin, L. Owen-Schaub, R. Pandita, S. Pathak, Induction of chromosomal rearrangements by tumour necrosis factors produced by primary B lymphoblastoid cells derived from cancer patients, Lymphokine Cytokine Res. 12 (1993) 9-19.
6. I.C. Green, J.M. Cunningham, C.A. Delaney, M.A. Titheradge, J.G. Mabley, M.H.L. Green, Effects of cytokines and nitric oxide donors on insulin secretion, cyclic nucleotides, glucose metabolism and DNA damage: relation to nitric oxide synthase activity and nitrite production in Insulin secretion and pancreatic B-cell research, in: P.R. Flatt, S. Lenzen (Eds.), Smith-Gordon Publ., UK., 1994.
7. I.C. Green, C. A Delaney, J.M. Cunningham, J.G. Mabley, M. di Matteo, M.H.L. Green, Cytokines, nitric oxide DNA damage and insulin-secreting cells, Environ. Mut. Res. Commun. 16 (1995) 245-253.
8. C.A. Delaney, M.H.L. Green, J.E. Löwe, I.C. Green, Endogenous nitric oxide induced by interleukin-1 β in rats islets of Langerhans and HIT-T15 cells causes significant DNA damage as measured by the 'comet' assay, FEBS 33 (1993) 291-295.
9. A. Dunger, J.M. Cunningham, C.A. Delaney, J.E. Löwe, M.H.L. Green, A.J. Bone, I.C. Green, Tumor necrosis factora and interferony inhibit insulin secretion and cause DNA damage in unweaned-rat islets: extent of nitric oxide involvement, Diabetes 45 (1996) 183-189.
10. S. Moncada, The L-arginine:nitric oxide pathway, Acta Physiol. Scand. 145 (1992) 201-227.
11. Y. Wang, T.A. Russo, O. Kwon, S. Chanock, S.C. Rumsey, M. Levine, Ascorbate recycling in human neutrophils: induction by bacteria, Proc. Natl. Acad. Sei. USA 94 (1997) 13816-13819.
12. H. Ohshima, H. Bartsch, Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis, Mutat. Res. 305 (1994) 253-264.
13. D.T. Efron, S.J. Kirk, M.C. Regan, H.L. Wasserkrug, A. Barbul, Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis, Surgery 110 (1991) 327-334.
14. N. Yajima, Y. Kurata, T. Sawai, Y. Takeshita, Comparative studies in induction of micronuclei by three genetically recombinant and urinary human erythropoietins, Mutagenesis 8 (1993) 237-241.
15. N. Yajima, Y. Kurata, T. Sawai, Y. Takeshita, Induction of micronucleated erythrocytes by recombinant human erythropoietin, Mutagenesis 8 (1993) 221-229.
16. N. Yajima, Y. Kurata, T. Sawai, Y. Takeshita, Genotoxicity of genetic recombinant human erythropoietin in a novel test system, Mutagenesis 8 (3) (1993) 231-236.
17. O. Hirai, Y. Miyamae, Y. Fujino, H. Izumi, A. Miyamoto, H. Noguchi, Prior bleeding enhances the sensitivity of the in vivo micronucleus test, Mutat. Res. 264 (1991) 109-114.
18. G. Steinheider, R. Neth, H. Marquardt, Evaluation of nongenotoxic and genotoxic factors modulating the frequency of micronucleated erythrocytes in the peripheral blood of mice, Cell. Biol. Toxicol. 1 (1985) 197-211.
19. H.E. Holden, Phenolphthalein: a sheep in wolf's clothing?, Environ. Mol. Mutagen. 31 (1998) 103-104.
20. P.P.W. van Buul, P. van Buul-Offers, Clastogenic effects of biosynthetic human growth hormone in Snell dwarf mice and CHO cells in vitro, Mutat. Res. 127 (1984) 61-64.
21. B. Tedeschi, G.L. Spadoni, M.L. Sanna, P. Vernole, D. Caporossi, S. Cianfarani, B. Nicoletti, B. Boscherini, Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone, Hum. Genet. 91 (1993) 459-463.
22. D.B. Allen, A.C. Rundle, D.A. Graves, S.L. Blethen, Risk of leukemia in children treated with human growth hormone: review and reanalysis, J. Pediatr. 131 (1997) S32-S36.
23. S.E. Hankinson, W.C. Willett, O.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, B. Rosner, F.E. Speizer, M. Pollak, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet 351 (1998) 1393-1396.
24. H.E. Jones, C.L. Eaton, D. Barrow, C.M. Dutkowski, J.M. Gee, K. Griffiths, Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines, Prostate 30 (1997) 219-231.
25. B.N. Ames, L.S. Gold, Too many rodent carcinogens: mitogenesis increases mutagenesis, Science 249 (1990) 970-971.
26. C. Johannes, W.D. Heller, P. Eke, G. Obe, Frequencies of polycentric chromosomes following combinational treatments of Chinese hamster ovary cells with restriction endonucleases and X-rays, bleomycin or DNase I, Mutat. Res. 373 (1997)237-244.
27. O.A. Folie, E. Boccardo, G. Obe, Localisation of chromosome breakpoints induced by DNAse I in Chinese hamster ovary (CHO) cells, Chromosoma 106 (1997) 391-399.
28. J.D. Green, Pharmaco-toxicological report: pulmozyme rhDNAse Genentech Hum, Exp. Toxicol. 13 (1994) 1-42.
29. O.N. Ilinskaya, O.B. Ivanchenko, N.S. Karamova, Bacterial ribonuclease: mutagenic effect in bacterial test systems, Mutagenesis 10(1995) 165-170.
30. O.N. Ilinskaya, N.S. Karamova, O.B. Ivanchenko, L.V. Kipenskaya, SOS-inducing ability of native and mutant microbial ribonucleases, Mutat. Res. 354 (1996) 203-209.
31. M. Kondo, T. Ogawa, Y. Matsubara, A. Mizutani, S. Murata, M. Kitagawa, Safety evaluation of lipase G from Penicillium camembertii, Food Chem. Toxicol. 32 (1994) 685-696.
32. A. Broadmeadow, C. Clare, A.S. De Boer, An overview of the safety evaluation of the Rhizomucor miehei lipase enzyme, Food Addit. Contam. 11 (1994) 105-119.
33. M. Stavnsbjerg, A.S. DeBoer, B.F. Jensen, Safety evaluation of lipase from Mucor-Mihei for inter-esterification of edible oils and fats, Food Addit. Contam. 5 (1988) 251-265.
34. M. Ishidate, Jr. Data Book of Chromosomal Aberration Test In Vitro, Elsevier, Amsterdam, 1988.
35. M. Cerna, Mutagenicity of β-glucuronidase in the Ames test, Mutat. Res. 143 (1985) 167-172.
36. W.W. Nichols, B.J. Ledwith, S.V. Manam, P.J. Troilo, Potential DNA vaccine integration into host cell genome, Ann. NY Acad. Sei. 772 (1995) 30-39.
37. P.D. Minor, Regulatory issues in the use of DNA vaccines, Ann. NY Acad. Sei. 772 (1995) 170-177.
38. S.M. Galloway, Genotoxicity tesing of pharmaceuticals: the need for a rational test design, Presentation at the 25th Annual Meeting EEMS, Nordwijkerhout, 1995.
39. G. Calarota, S. Bratt, A.-C. Nordlund, V. Leandersson, B. Sandström, B. Wahren, Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients, Lancet 351 (1998) 1320-1325.
40. G.M. Arndt, GH rank colocalization of antisense RNAs and ribozymes with their target mRNAs, Genome 40 (1997) 785-797.
41. G. Wang, M.M. Seidman, P.M. Glazer, Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair, Science 271 (1996) 802-805.
42. P.C. Hanawalt, Transcription-coupled repair and human disease, Science 266 (1994) 1957-1958.
43. B.A. Bunnell, R.A. Morgan, Gene therapy for infectious diseases, Clin. Microbiol. Rev. 11 (1998) 42-56.
44. L.A. Couture, D.T. Stinchcomb, Anti-gene therapy: the use of ribozymes to inhibit gene function, Trends Genet. 12 (1996) 510-515.
45. E.A. Griffin Jr., Z. Qin, W.J. Michels Jr., A.M. Pyle, Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2′-hydroxyl groups, Chem. Biol. 2 (1995) 761-770.
46. D.J. Kirkland, N.N. Kim, Special considerations for conducting genotoxicity tests with protein materials, Mutagenesis 10 (1995) 393-398.
47. S. Dean, Meeting report of the Industrial Genotoxicology Group. London, December 1995, Mutagenesis 12 (1997) 49-50.
48. G. Sofer, Biotechnology product validation: Part 4. Clearance of impurities from protein and peptide biotherapeutics, Pharmaceutical Technology Europe (May 1994) 29-32.
49. G. Sofer, L. Hagel, in: Handbook of Process Chromatography: A Guide to Optimization, Scale-up and Validation, Academic Press, 1997, 149 pp.
50. L. Müller, P. Kasper, Human biological relevance and the use of threshold arguments in regulatory genotoxicology assessment: experience with pharmaceuticals, Mutat. Res. (submitted).